The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma
- PMID: 12167415
- DOI: 10.1016/s1368-8375(02)00029-5
The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma
Abstract
c-erbB receptor signalling induces pleiotropic responses and influences several biological functions involved in the pathogenesis and progression of HNSCC. Aberrant expression of multiple c-erbB receptors and ligands is frequently observed in tumour cells. EGFR appears to be a dominant factor controlling the malignant phenotype in HNSCC at least in part via regulation of molecules involved in invasive and angio-/lymphangiogenic processes. Although c-erbB-2 is an orphan receptor, the formation of heterodimer complexes appears to be an important mechanism for inter-receptor activation and synergistic signal transduction. The roles of c-erbB-3 and c-erbB-4 in HNSCC progression are less clear. However, their ability to form heterodimers with other c-erbB family members enhances proliferation and invasion in HNSCC cells. At least two major downstream signalling pathways, MAPK and PI3K, are involved in the transcriptional regulation of proteases and cytokines implicated in invasion and angiogenesis. Studies using clinical specimens confirmed experimental data that co-operative signalling of c-erbB receptors may play a significant role in the pathogenesis of HNSCC. Most therapeutic studies in HNSCC so far have focused on the strategies targeting of EGFR. Due to the complexity of the system both at the receptor and ligand levels and the integrated biological functions of the c-erbB family in HNSCC, the effect of combined c-erbB blockade (or their downstream signalling pathways) on HNSCC progression should be explored.
Similar articles
-
Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.Clin Exp Metastasis. 1999;17(7):631-9. doi: 10.1023/a:1006751016860. Clin Exp Metastasis. 1999. PMID: 10845563
-
C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors.Oral Oncol. 2002 Jan;38(1):73-80. doi: 10.1016/s1368-8375(01)00029-x. Oral Oncol. 2002. PMID: 11755824
-
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.Cancer Lett. 2016 Jul 10;377(1):1-10. doi: 10.1016/j.canlet.2016.04.023. Epub 2016 Apr 18. Cancer Lett. 2016. PMID: 27090738
-
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
-
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).Cancer Treat Rev. 2014 May;40(4):567-77. doi: 10.1016/j.ctrv.2013.10.002. Epub 2013 Oct 12. Cancer Treat Rev. 2014. PMID: 24216225 Review.
Cited by
-
Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients.Br J Cancer. 2004 Jan 26;90(2):443-8. doi: 10.1038/sj.bjc.6601532. Br J Cancer. 2004. PMID: 14735191 Free PMC article. Clinical Trial.
-
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.Life Sci Alliance. 2020 May 7;3(6):e201900545. doi: 10.26508/lsa.201900545. Print 2020 Jun. Life Sci Alliance. 2020. PMID: 32381551 Free PMC article.
-
Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma.Int J Exp Pathol. 2003 Dec;84(6):259-65. doi: 10.1111/j.0959-9673.2004.00361.x. Int J Exp Pathol. 2003. PMID: 14748745 Free PMC article.
-
EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.Curr Oncol Rep. 2008 Mar;10(2):176-84. doi: 10.1007/s11912-008-0027-6. Curr Oncol Rep. 2008. PMID: 18377832 Review.
-
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.Front Genet. 2015 Feb 4;6:17. doi: 10.3389/fgene.2015.00017. eCollection 2015. Front Genet. 2015. PMID: 25699077 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous